Factors influencing credentialing of interventionists in the CREST-2 trial.
Carotid atherosclerosis
Carotid stent
Clinical trial
Stroke prevention
Journal
Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
11
12
2018
accepted:
01
05
2019
pubmed:
30
7
2019
medline:
30
7
2020
entrez:
30
7
2019
Statut:
ppublish
Résumé
The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a pair of randomized trials assessing the relative efficacy of carotid revascularization in the setting of intensive medical management (IMM) in patients with asymptomatic high-grade atherosclerotic stenosis. One of the trials assesses IMM with or without carotid artery stenting (CAS). Given the low risk of stroke in nonrevascularized patients receiving IMM, it is essential that there be low periprocedural risk of stroke for CAS if it is to show incremental benefit. Thus, credentialing of interventionists to ensure excellence is vital. This analysis describes the protocol-driven approach to credentialing of CAS interventionists for CREST-2 and its outcomes. To be eligible to perform stenting in CREST-2, interventionists needed to be credentialed on the basis of a detailed Interventional Management Committee (IMC) review of data from their last 25 consecutive cases during the past 24 months along with self-reported lifetime experience case numbers. When necessary, additional prospective cases performed in a companion registry were requested after webinar training. Here we review the IMC experience from the first formal meeting on March 21, 2014 through October 14, 2017. The IMC had 102 meetings, and 8311 cases submitted by 334 interventionists were evaluated. Most were either cardiologists or vascular surgeons, although no single specialty made up the majority of applicants. The median total experience was 130 cases (interquartile range [IQR], 75-266; range, 25-2500). Only 9% (30/334) of interventionists were approved at initial review; approval increased to 46% (153/334) after submission of new cases with added training and re-review. The median self-reported lifetime case experience for those approved was 211.5 (IQR, 100-350), and the median number of cases submitted for review was 30 (IQR, 27-35). The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P < .00001). Identification of interventionists who were deemed sufficiently skilled for CREST-2 has required substantial oversight and a controlled system to judge current skill level that controls for specialty-based practice variability, procedural experience, and periprocedural outcomes. High-volume interventionists, particularly those with more recent experience, were more likely to be approved to participate in CREST-2. Primary approval was not affected by operator specialty.
Sections du résumé
BACKGROUND
The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a pair of randomized trials assessing the relative efficacy of carotid revascularization in the setting of intensive medical management (IMM) in patients with asymptomatic high-grade atherosclerotic stenosis. One of the trials assesses IMM with or without carotid artery stenting (CAS). Given the low risk of stroke in nonrevascularized patients receiving IMM, it is essential that there be low periprocedural risk of stroke for CAS if it is to show incremental benefit. Thus, credentialing of interventionists to ensure excellence is vital. This analysis describes the protocol-driven approach to credentialing of CAS interventionists for CREST-2 and its outcomes.
METHODS
To be eligible to perform stenting in CREST-2, interventionists needed to be credentialed on the basis of a detailed Interventional Management Committee (IMC) review of data from their last 25 consecutive cases during the past 24 months along with self-reported lifetime experience case numbers. When necessary, additional prospective cases performed in a companion registry were requested after webinar training. Here we review the IMC experience from the first formal meeting on March 21, 2014 through October 14, 2017.
RESULTS
The IMC had 102 meetings, and 8311 cases submitted by 334 interventionists were evaluated. Most were either cardiologists or vascular surgeons, although no single specialty made up the majority of applicants. The median total experience was 130 cases (interquartile range [IQR], 75-266; range, 25-2500). Only 9% (30/334) of interventionists were approved at initial review; approval increased to 46% (153/334) after submission of new cases with added training and re-review. The median self-reported lifetime case experience for those approved was 211.5 (IQR, 100-350), and the median number of cases submitted for review was 30 (IQR, 27-35). The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P < .00001).
CONCLUSIONS
Identification of interventionists who were deemed sufficiently skilled for CREST-2 has required substantial oversight and a controlled system to judge current skill level that controls for specialty-based practice variability, procedural experience, and periprocedural outcomes. High-volume interventionists, particularly those with more recent experience, were more likely to be approved to participate in CREST-2. Primary approval was not affected by operator specialty.
Identifiants
pubmed: 31353274
pii: S0741-5214(19)31449-1
doi: 10.1016/j.jvs.2019.05.035
pmc: PMC6980974
mid: NIHMS1063445
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02089217']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
854-861Subventions
Organisme : NINDS NIH HHS
ID : U01 NS080165
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS080168
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS086872
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Références
N Engl J Med. 2016 Mar 17;374(11):1011-20
pubmed: 26886419
Catheter Cardiovasc Interv. 2016 Feb 1;87(2):188-99
pubmed: 26602705
Semin Vasc Surg. 2017 Mar;30(1):2-7
pubmed: 28818255
J Neuroimaging. 2008 Oct;18(4):433-47
pubmed: 18315594
Health Technol Assess. 2017 Oct;21(57):1-40
pubmed: 29019319
Ann Surg. 2016 Dec;264(6):896-903
pubmed: 27192348
Prog Cardiovasc Dis. 2011 Jul-Aug;54(1):14-21
pubmed: 21722782
J Stroke Cerebrovasc Dis. 2010 Mar;19(2):153-62
pubmed: 20189092
Stroke. 2014 Nov;45(11):3325-9
pubmed: 25213339
Stroke. 2011 Mar;42(3):675-80
pubmed: 21307169
Int J Stroke. 2017 Oct;12(7):770-778
pubmed: 28462683
N Engl J Med. 2006 Oct 19;355(16):1660-71
pubmed: 17050890
JACC Cardiovasc Interv. 2011 Feb;4(2):235-46
pubmed: 21349464
Lancet. 2015 Feb 7;385(9967):529-38
pubmed: 25453443
N Engl J Med. 2016 Mar 17;374(11):1021-31
pubmed: 26890472
Lancet Neurol. 2008 Oct;7(10):893-902
pubmed: 18774746